Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
WHO Drug Information Vol. 16, No. 1, 2002
(2002; 116 pages) View the PDF document
Table of Contents
View the documentPreface
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsSafety Information
Open this folder and view contentsCurrent Topics
Open this folder and view contentsRegulatory and Safety Action
Open this folder and view contentsQuality Assurance Issues
Open this folder and view contentsRecent Publications and Sources of Information
View the documentProposed International Nonproprietary Names: List 86
View the documentRecommended International Nonproprietary Names (Rec. INN): List 47
View the documentSelected WHO publications of related interest
 

Recommended International Nonproprietary Names (Rec. INN): List 47

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 47

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1-85) and Recommended (1-45) International Nonproprietary Names can be found in Cumulative List No. 10, 2002 (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 47

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d’autres listes de Dénominations communes internationales proposées (1-85) et recommandées (1-45) dans la Liste récapitulative No. 10, 2002 (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 47

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1-85) y Recomendadas (1-45) se encuentran reunidas en Cumulative List No. 10, 2002 (disponible sólo en CD-ROM)

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

   

acidum gadocoleticum

 

gadocoletic acid

trihydrogen [3β-[[(4S)-4-[bis[2-[bis[(carboxy-KO)methyl]amino-KN]ethyl]amino-KN]-4-(carboxy-KO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]=gadolinate(3-)

acide gadocolétique

trihydrogéno[3β-[[(4S)-4-[bis[2-[bis[(carboxy-KO)méthyl]amino-N]éthyl]amino-KN]-4-(carboxy-KO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]=gadolinate(3-)

ácido gadocolético

trihidrógeno[3β-[[(4S)-4-[bis[2-[bis[(carboxi-KO)metil]amino-KN]etil]amino-KN]-4-(carboxi-KO)butanoil]amino]-12α-hidroxi-5β-colan-24-ato(6-)]gadolinato(3-)

 

C41H63GdN4O14

   
 

   

afeletecanum

 

afeletecan

camptothecin, ester with N-[[p-[(3-O-methyl-β-L-fucopyranosyl)oxy]phenyl]=thiocarbamoyl]-L-histidyl-L-valine

afélétécan

(2S)-2-[[(2S)-3-(1H-imidazol-4-yl)-2-[[[[4-[(3-O-méthyl-6-désoxy-β-L-galactopyranosyl)oxy]phényl]amino]thiocarbonyl]amino]propanoyl]amino]-3-méthylbutanoate de (4S)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1H-pyrano[3’,4’:6,7]indolizino[1,2-b]quinoléin-4-yle

afeletecán

ester de la camptotecina con N-[[p-[(3-O-metil-β-L-fucopiranosil)oxi]fenil]=tiocarbamoil]-L-histidil-L-valina

 

C45H49N7O11S

   
 

   

alfimeprasum

 

alfimeprase

[3-L-serine]fibrolase-(3-203)-peptide (fibrolase: fibrinolytic enzyme isolated from Agkistrodon contrix contrix venom)

alfiméprase

[3-L-sérine]fibrolase-(3-203)-peptide (fibrolase: enzyme fibrinolytique extraite de venin d’Agkistrodon contrix contrix)

alfimeprasa

[3-L-serina]fibrolasa-(3-203)-péptido (fibrolasa: enzime fibrinolítica extraida de veneno de Agkistrodon contrix contrix)

 

C985H1541N285O301S12

   
 

   

alicaforsenum

 

alicaforsen

2’-deoxy-(R)-P-thioguanylyt-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-deoxy-(R)-P-thioadenylyl-(3’→5’)-2’-deoxy-(R)-P-thioadenylyl-(3’→5’)-2’-deoxy-(R)-P-thioguanylyl-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-(R)-P-thiothymidylyl-(3’→5’)-2’-deoxy-(R)-P-thioguanylyl-(3’→5’)-2’-deoxy-(R)-P-thioguanylyl-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-deoxy-(R)-P-thioadenylyl-(3’→5’)-(R)-P-thiothymidylyl-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-deoxy-(R)-P-thioguanylyl-(3’→5’)-(R)-P-thiothymidylyl-(3’→5’)-2’-deoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-deoxyadenosine nonadecasodium salt

alicaforsen

2’-désoxy-(R)-P-thioguanylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-désoxy-(R)-P-thioadénylyl-(3’→5’)-2’-désoxy-(R)-P-thioadénylyl-(3’→5)-2’-désoxy-(R)-P-thioguanylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-(R)-P-thiothymidylyl-(3’→5’)-2’-désoxy-(R)-P-thioguanylyl-(3’→5’)-2’-désoxy-(R)-P-thioguanylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-désoxy-(R)-P-thioadénylyl-(3’→5’)-(R)-P-thiothymidylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-désoxy-(R)-P-thioguanylyl-(3’→5’)-(R)-P-thiothymidylyl-(3’→5’)-2’-désoxy-(R)-P-thiocytidylyl-(3’→5’)-2’-désoxyadénosine nonadécasodique

alicaforseno

2’-desoxi-(R)-P-tioguanilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-2’-desoxi-(R)-P-tioadenilil-(3’→5’)-2’-desoxi-(R)-P-tioadenilil-(3’→5’)-2’-desoxi-(R)-P-tioguanilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-(R)-P-tiotimidilil-(3’→5’)-2’-desoxi-(R)-P-tioguanilil-(3’→5’)-2’-desoxi-(R)-P-tioguanilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-2’-desoxi-(R)-P-tioadenilil-(3’→5’)-(R)-P-tiotimidilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-2’-desoxi-(R)-P-tioguanilil-(3’→5’)-(R)-P-tiotimidilil-(3’→5’)-2’-desoxi-(R)-P-tiocitidilil-(3’→5’)-2’-desoxiadenosina nonadecasódica

 

C192H225N75Na19O98P19S19

alilusemum

 

alilusem

7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4(1H)-one (E)-O-sulfooxime

alilusem

(E)-O-sulfooxime de 7-chloro-1-(2-méthylbenzoyl)-2,3-dihydroquinoléin-4(1H)-one

alilusem

(E)-O-sulfooxima de 7-cloro-1-(2-metilbenzoil)-2,3-dihidroquinolin-4(1H)-ona

 

C17H15ClN2O5S

   
 

   

ambrisentanum

 

ambrisentan

(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

ambrisentan

(+)-acide (2S)-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3-méthoxy-3,3-diphénylpropanoïque

ambrisentán

(+)-ácido (2S)-2-[(4,6-dimetilpirimidin-2-il)oxi]-3-metoxi-3,3-difenilpropanoico

 

C22H22N2O4

   
 

   

amdoxovirum

 

amdoxovir

[(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol

amdoxovir

[(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-yl]méthanol

amdoxovir

[(2R,4R)-4-(2,6-diamino-9H-purin-9-il)-1,3-dioxolan-2-il]metanol

 

C9H12N6O3

   
 

   

amelubantum

 

amelubant

ethyl [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]benzyl]=oxy]phenyl](imino)methyl]carbamate

amélubant

[[4-[[3-[[4-[1-(4-hydroxyphényl)-1-méthyléthyl]phénoxy]méthyl]benzyl]oxy]=phényl](imino)méthyl]carbamate d’éthyle

amelubant

[[4-[[3-[[4-[1-(4-hidroxifenil)-1-metiletil]fenoxi]metil]bencil]oxi]fenil](imino)metil]=carbamato de etilo

 

C33H34N2O5

   
 

   

amotosalenum

 

amotosalen

3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g][1]benzopyran-7-one

amotosalène

3-[(2-aminoéthoxy)méthyl]-2,5,9-triméthyl-7H-furo[3,2-g][1]benzopyran-7-one

amotosaleno

3-[(2-aminoetoxi)metil]-2,5,9-trimetil-7H-furo[3,2-g][1]benzopiran-7-ona

 

C17H19NO4

   
 

   

bimatoprostum

 

bimatoprost

(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide

bimatoprost

(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phénylpent-1-ényl]cyclopentyl]-N-éthylhept-5-énamide

bimatoprost

(Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-[(1E,3S)-3-hidroxi-5-fenilpent-1-enil]ciclopentil]-N-etilhept-5-enamida

 

C25H37NO4

   
 

   

caldaretum

 

caldaret

5-methyl-2-(piperazin-1-yl)benzenesulfonic acid

caldaret

acide 5-méthyl-2-(pipérazin-1-yl)benzènesulfonique

caldaret

ácido 5-metil-2-(piperazin-1-il)bencenosulfónico

 

C11H16N2O3S

   
 

   

cipralisantum

 

cipralisant

4-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole

cipralisant

4-[(1R,2R)-2-(5,5-diméthylhex-1-ynyl)cyclopropyl]-1H-imidazole

cipralisant

4-[(1R,2R)-2-(5,5-dimetilhex-1-inil)ciclopropil]-1H-imidazol

 

C14H20N2

   
 

   

darbepoetinum alfa

 

darbepoetin alfa

[30-L-asparagine,32-L-thronine,87-L-valine,88-L-asparagine, 90-L-threonine]erythropoietin (human)

darbépoétine alfa

[30-L-asparagine,32-L-thréonine,87-L-valine,88-L-asparagine, 90-L-thréonine]érythropoiétine humaine

darbepoetina alfa

[30-L-asparagina,32-L-treonina,87-L-valina,88-L-asparagina, 90-L-treonina]eritropoietina humana

 

C800H1300N228O243S5

   
 

   

drotrecoginum alfa (activatum)

 

drotrecogin alfa (activated)

blood coagulation factor XIV (human)

drotrécogine alfa (activé)

facteur XIV humain de coagulation sanguine

drotrecogina alfa (activada)

factor XIV de coagulación sanguínea (humano)

 

C2071H3165N581O640S31

   
 

   

ecalcidenum

 

ecalcidene

1-[(5Z,7E,20S)-1α,3β-dihydroxy-9,10-secochola-5,7,10(19)-trien-24-oyl]piperidine

écalcidène

1-[(5Z,7E,20S)-1α,3β-dihydroxy-9,10-sécochola-5,7,10(19)-trién-24-oyl]pipéridine

ecalcideno

1-[(5Z,7E,20S)-1α,3β-dihidroxi-9,10-secocola-5,7,10(19)-trien-24-oil]piperidina

 

C29H45NO3

   
 

   

efalizumabum

 

efalizumab

immunoglobulin G1, anti-(human antigen CD11a) (human-mouse monoclonal hu1124 γ1-chain), disulfide with human-mouse monoclonal hu1124 light chain, dimer

éfalizumab

immunoglobuline G1, anti-(antigène CD11a humain) (chaîne γ1 de l’anticorps monoclonal de souris humanisé hu1124), dimère du disulfure avec la chaîne légère de l’anticorps monoclonal de souris humanisé hu1124

efalizumab

inmunoglobulina G1, anti-(antígeno CD11a humano) (cadena γ1 del anticuerpo monoclonal humanizado de ratón hu1124), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón hu1124

   

enfuvirtidum

 

enfuvirtide

acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-L-α-glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl-L-α-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide

enfuvirtide

acétyl-L-tyrosyl-L-thréonyl-L-séryl-L-leucyl-L-isoleucyl-L-histidyl-L-séryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-séryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-L-α-glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl-L-α-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-séryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phénylalaninamide

enfuvirtida

acetil-L-tirosil-L-treonil-L-seril-L-leucil-L-isoleucil-L-histidil-L-seril-L-leucil-L-isoleucil-L-α-glutamil-L-α-glutamil-L-seril-L-glutaminil-L-asparaginil-L-glutaminil-L-glutaminil-L-α-glutamil-L-lisil-L-asparaginil-L-α-glutamil-L-glutaminil-L-α-glutamil-L-leucil-L-leucil-L-α-glutamil-L-leucil-L-α-aspartil-L-lisil-L-triptofil-L-alanil-L-seril-L-leucil-L-triptofil-L-asparaginil-L-triptofil-L-fenilalaninamida

 

C204H301N51O64

   
 

   

epafipasum

 

epafipase

2-acetyl-1-alkyl-sn-glycero-3-phosphocholine deacetylase-(6-400)-peptide (human)

épafipase

désacétylase-(6-400)-peptide (humaine) de la 2-acétyl-1-alkyl-sn-glycéro-3-phosphocholine

epafipasa

1-O-alquil-2-acetil-sn-glicero-3-fosfocolina 6-400-desacetilasa (humana)

 

C2016H3107N545O586S14

   
 

   

epoetinum delta

 

epoetin delta

1-165-erythropoietin (human HMR4396), glycoform δ

époétine delta

1-165-érythropoiétine (humaine HMR4396), glycoforme δ

epoetina delta

1-165-eritropoietina (humana HMR4396), glicoforma δ

 

C809H1301N229O240S5

   
 

   

erlotinibum

 

erlotinib

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

erlotinib

N-(3-éthynylphényl)-6,7-bis(2-méthoxyéthoxy)quinazolin-4-amine

erlotinib

N-(3-etinilfenil)-6,7-bis(2-metoxietoxi)quinazolin-4-amina

 

C22H23N3O4

   
 

   

febuxostatum

 

febuxostat

2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

fébuxostat

acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-5-carboxylique

febuxostat

ácido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxílico

 

C16H16N2O3S

   
 

   

feloprentanum

 

feloprentan

(2S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3,3-diphenylpropanoic acid

féloprentan

acide (2S)-3-[2-(3,4-diméthoxyphényl)éthoxy]-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3,3-diphénylpropanoïque

feloprentán

ácido (2S)-3-[2-(3,4-dimetoxifenil)etoxi]-2-[(4,6-dimetilpirimidin-2-il)oxi]-3,3-difenilpropanoico

 

C31H32N2O6

   
 

   

finafloxacinum

 

finafloxacin

(-)-8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

finafloxacine

(-)-acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoléine-3-carboxylique

finafloxacino

(-)-ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4aS,7aS)-hexahidropirrolo[3,4-b]-1,4-oxazin-6(2H)-il)-4-oxo-1,4-dihidroquinolina-3-carboxílico

 

C20H19FN4O4

   
 

   

gadomelitolum

 

gadomelitol

hydrogen [2,2’,2’’,2’’’-[1,4,7,10-tetraazacyclododecane-1,4,7,10-triyl]tetrakis=[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyl]phenyl]amino]-2-oxoethyl]carbamoyl]phenyl]=carbamoyl]phenyl]amino]-2-oxoethyl]amino]-5-oxopentanoato](4-)]=gadolinate(1-)

gadomélitol

hydrogéno-[2,2’,2’’,2’’’-[1,4,7,10-tétraazacyclododécane-1,4,7,10-triyl]tétrakis [5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyl]phényl]amino]-2-oxoéthyl]carbamoyl]phényl]=carbamoyl]phényl]amino]-2-oxoéthyl]amino]-5-oxopentanoato](4-)]=gadolinate(1-)

gadomelitol

hidrógeno-[2,2’,2’’,2’’’-[1,4,7,10-tetraazaciclododecano-1,4,7,10-triil]tetrakis=[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahidroxihexil-2,4,6-tribromo]carbamoil]fenil]amino]-2-oxoetil]carbamoil]fenil]carbamoil]fenil]=amino]-2-oxoetil]amino]-5-oxopentanoato](4-)]gadolinato(1-)

 

C228H313Br12GdN32O116

   
 

   

garnocestimum

 

garnocestim

5-73-macrophage inflammatory protein 2α (human gene gro2)

garnocestim

CXC chimiokine GROβ-(5-73)-peptide (GROβ: protéine inflammatoire humaine sécrétée par les macrophages)

garnocestim

CXC quimiokina GROβ-(5-73)-péptido (GROβ: proteína inflamatoria humana secretada por los macrófagos)

 

C325H557N97O95S6

   
 

   

gefitinibum

 

gefitinib

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

géfitinib

N-(3-chloro-4-fluorophényl)-7-méthoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

gefitinib

N-(3-cloro-4-fluorofenil)-7-metoxi-6-[3-(morfolin-4-il)propoxi]quinazolin-4-amina

 

C22H24ClFN4O3

   
 

   

ingliforibum

 

ingliforib

5-chloro-N-[(1S,2R)-1-benzyl-3-(cis-3,4-dihydroxypyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1H-indole-2-carboxamide

ingliforib

5-chloro-N-[(1S,2R)-1-benzyl-3-(cis-3,4-dihydroxypyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1H-indole-2-carboxamide

ingliforib

5-cloro-N-[(1S,2R)-1-bencil-3-(cis-3,4-dihidroxipirrolidin-1-il)-2-hidroxi-3-oxopropil]-1H-indol-2-carboxamida

 

C23H24ClN3O5

   
 

   

ipravacainum

 

ipravacaine

(2RS)-1-(cyclopropylmethyl)-2’,6’-dimethyl-2-piperidinecarboxanilide

ipravacaïne

(2RS)-1-(cyclopropylméthyl)-N-(2,6-diméthylphényl)pipéridine-2-carboxamide

ipravacaína

(2RS)-1-(ciclopropilmetil)-N-(2,6-dimetilfenil)piperidina-2-carboxamida

 

C18H26N2O

   
 

   

isegananum

 

iseganan

L-arginylglycylglycyl-L-leucyl-L-cysteinyl-L-tyrosyl-L-cysteinyl-L-arginylglycyl-L-arginyl-L-phenylalanyl-L-cysteinyl-L-valyl-L-cysteinyl-L-valylglycyl-L-argininamide cyclic (5→14),(7→12)-bis(disulfide)

iséganan

(5→14),(7→12)-bis(disulfure cyclique) de L-arginyl-glycyl-glycyl-L-leucyl-L-cystéinyl-L-tyrosyl-L-cystéinyl-L-arginyl-glycyl-L-arginyl-L-phénylalanyl-L-cystéinyl-L-valyl-L-cystéinyl-L-valyl-glycyl-L-argininamide

iseganán

(5→14),(7→12)-bis(disulfuro cíclico) de L-arginil-glicil-glicil-L-leucil-L-cisteinil-L-tirosil-L-cisteinil-L-arginil-glicil-L-arginil-L-fenilalanil-L-cisteinil-L-valil-L-cisteinil-L-valil-glicil-L-argininamida

 

C78H126N30O18S4

   
 

   

labetuzumabum

 

labetuzumab

immunoglobulin G, anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14γ-chain), disulfide with human-mouse monoclonal hMN-14K-chain, dimer

labétuzumab

immunoglobuline G, anti-(antigène carcinoembryonnaire humain) (chaîne-γ de l’anticorps monoclonal de souris humanisé hMN-14), dimère du disulfure avec la chaîne-K de l’anticorps monoclonal de souris humanisé hMN-14

labetuzumab

inmunoglobulina G, anti-(antígeno carcinoembrionario humano) (cadena-γ del anticuerpo monoclonal humanizado de ratón hMN-14), dímero del disulfuro con la cadena-K del anticuerpo monoclonal humanizado de ratón hMN-14

   

laniquidarum

 

laniquidar

methyl 6,11-dihydro-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate

laniquidar

11-[1-[2-[4-(quinoléin-2-ylméthoxy)phényl]éthyl]pipéridin-4-ylidène]-6,11-dihydro-5H-imidazo[2,1-b][3]benzazépine-3-carboxylate de méthyle

laniquidar

11-[1-[2-[4-(quinolin-2-ilmetoxi)fenil]etil]piperidin-4-ilideno]-6,11-dihidro-5H-imidazo[2,1-b][3]benzazepina-3-carboxilato de metilo

 

C37H36N4O3

   
 

   

lapisteridum

 

lapisteride

N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide

lapistéride

N-[1-(4-méthoxyphényl)-1-méthyléthyl]-3-oxo-4-aza-5α-androst-1-ène-17β-carboxamide

lapisterida

N-[1-(4-metoxifenil)-1-metiletil]-3-oxo-4-aza-5α-androst-1-eno-17β-carboxamida

 

C29H40N2O3

   
 

   

laquinimodum

 

laquinimod

5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide

laquinimod

5-chloro-N-éthyl-4-hydroxy-1-méthyl-2-oxo-N-phényl-1,2-dihydroquinoléine-3-carboxamide

laquinimod

5-cloro-N-etil-4-hidroxi-1-metil-2-oxo-N-fenil-1,2-dihidroquinolina-3-carboxamida

 

C19H17ClN2O3

   
 

   

laronidasum

 

laronidase

8-L-histidine-α-L-iduronidase (human)

laronidase

[8-L-histidine]-α-L-iduronidase humaine

laronidasa

8-L-histidina-α-L-iduronidasa (humana)

 

C3169H4854N901O884S12

   
 

   

lirimilastum

 

lirimilast

2-(2,4-dichlorobenzoyl)-3-ureidobenzofuran-6-yl methanesulfonate

lirimilast

méthanesulfonate de 2-(2,4-dichlorobenzoyl)-3-uréidobenzofuran-6-yle

lirimilast

metanosulfonato de 2-(2,4-diclorobenzoil)-3-ureidobenzofuran-6-ilo

 

C17H12Cl2N2O6S

   
 

   

livaraparinum calcium

 

livaraparin calcium

calcium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-O-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-O-sulfo-structure at the reducing end of their chain; the mass-average molecular mass ranges between 3000 and 5000 with 75% is less than 8000; the degree of sulfatation is approximately 2 per disaccharidic unit

livaraparine calcique

sel calcique d’une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d’acide nitreux, d’héparine de muqueuse intestinale de porc; la majorité des composants de la livaraparine calcique possèdent une structure acide 2-O-sulfo-α-L-idopyranosuronique à l’extrémité non réductrice de leur chaîne et une structure 6-O-sulfatée à l’extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 3000 à 5000, 75% étant inférieur à 8000; le degré de sulfatation par unité disaccharide est voisin de 2

livaraparina cálcica

sal cálcica de una heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización con ácido nitroso; la mayoría de los componentes de la livaraparina cálcica tienen ácido 2-O-sulfo-α-L-idopiranosurónico en el extremo no reductor de la cadena y una estructura 6-O-sulfatada en el extremo reductor de la cadena; la masa molecular relativa media es de 3000 a 5000, siendo el 75% inferior a 8000; el grado de sulfatación por unidad de disacárido es aproximadamente 2

   

manifaxinum

 

manifaxine

(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol

manifaxine

(2S,3S,5R)-2-(3,5-difluorophényl)-3,5-diméthylmorpholin-2-ol

manifaxina

(2S,3S,5R)-2-(3,5-difluorofenil)-3,5-dimetilmorfolin-2-ol

 

C12H15F2NO2

   
 

   

miglustatum

 

miglustat

(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

miglustat

(2R,3R,4R,5S)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol

miglustat

(2R,3R,4R,5S)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol

 

C10H21NO4

   
 

   

miriplatinum

 

miriplatin

(SP-4-2)-[(1R,2R)-cyclohexane-1,2-diamine-N,N]=bis(tetradecanoato-O)platinum

miriplatine

(SP-4-2)-[(1R,2R)-cyclohexane-1,2-diamine-N,N]=bis(tétradécanoato-O)platine

miriplatino

(SP-4-2)-[(1R,2R)-ciclohexano-1,2-diamina-N,N’]=bis(tetradecanoato-O)platino

 

C34H68N2O4Pt

   
 

   

mirostipenum

 

mirostipen

[23-methionine]human myeloid progenitor inhibitory factor 1-(23-99)-peptide

mirostipen

[23-méthionine]facteur 1 d’inhibition du précurseur myéloïde humain-(23-99)-peptide

mirostipeno

[23-metionina]-(23-99)-péptido del factor 1 de inhibición del progenitor mieloide humano

 

C380H614N112O113S9

   
 

   

mureletecanum

 

mureletecan

poly[[N-(2-hydroxypropyl)methacrylamide]-co-[camptothecin ester with N-[6-(2-methacrylamidoacetamido)hexanoyl]glycine]-co-[N-[[(2-hydroxypropyl)carbamoyl]methyl]methacrylamide]]

murélétécan

copolymère de N-[(2RS)-2-hydroxypropyl]-2-méthylpropénamide, de N-[2-[[6-[[2-[[(4S)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1H-pyrano[3’,4’:6,7]indolizino[1,2-b]quinoléin-4-yl]oxy]-2-oxoéthyl]amino]-6-oxohexyl]amino]-2-oxoéthyl]-2-méthylpropénamide et de N-[2-[[(2RS)-2-hydroxypropyl]amino]-2-oxoéthyl]-2-méthylpropénamide

mureletecán

poli[[N-(2-hidroxipropil)metacrilamida]-co-[éster de camptotecina con N-[6-(2-metacrilamidoacetamido)hexanoil]glicina]-co-[N-[[(2-hidroxipropil)carbamoil]metil]metacrilamida]]

   
 

   

nasaruplasum beta

 

beta nasaruplase beta

prourokinase (enzyme-activating) human (clone pUK4/pUK18 protein moiety), glycosylated (murine cell line SP2/0)

nasaruplase bêta

prourokinase (activateur d’enzyme) humaine glycosylée dont le gène est cloné dans le vecteur pUK4/pUK18 et exprimée dans la lignée cellulaire murine SP2/0

nasaruplasa beta

prourokinasa (activador de enzima) humana glicosilada cuyo gen se clona en el vector pUK4/pUK18 y se expresa en la línea celular murina SP2/0

 

C2031H3121N585O601S31

   
 

   

netoglitazonum

 

netoglitazone

(5RS)-5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]thiazolidine-2,4-dione

nétoglitazone

(5RS)-5-[[6-[(2-fluorophényl)méthoxy]naphtalén-2-yl]méthyl]thiazolidine-2,4-dione

netoglitazona

(5RS)-5-[[6-[(2-fluorofenil)metoxi]naftalen-2-il]metil]tiazolidina-2,4-diona

 

C21H16FNO3S

   
 

   

ospemifenum

 

ospemifene

2-[p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]ethanol

ospémifène

(Z)-2-[4-(4-chloro-1,2-diphénylbut-1-ényl)phénoxy]éthanol

ospemifeno

2-[p-[(Z)-4-cloro-1,2-difenil-1-butenil]fenoxi]etanol

 

C24H23ClO2

   
 

   

pegfilgrastimum

 

pegfilgrastim

N-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with α-methyl-ω)-hydroxypoly(oxyethylene)

pegfilgrastim

N-(3-hydroxypropyl)méthionylfacteur de stimulation de colonie humain, 1-éther avec le α-méthyl-ω-hydroxypoly(oxyéthylène)

pegfilgrastim

N-(3-hidroxipropil)metionilfactor de estimulación de colonias humano, 1-éter con el α-metil-ω-hidroxipoli(oxietileno)

 

C849H1347N223O244S9,(C2H4O)n

   
 

   

pexelizumabum

 

pexelizumab

immunoglobulin, anti-(human complement C5 α-chain) (human-mouse monoclonal 5G1.1-SC single chain)

pexélizumab

immunoglobuline, anti-(chaîne-α du complément C5 humain) (mono chaîne de l’anticorps monoclonal de souris humanisé 5G1.1-SC)

pexelizumab

inmunoglobulina, anti-(cadena-α del complemento C5 humano) (mono cadena del anticuerpo monoclonal humanizado de ratón 5G1.1-SC)

   

pralnacasanum

 

pralnacasan

(1S,9S)-N-[(2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl]-9-[(isoquinolin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-H-pyridazino[1,2-a][1,2]=diazepine-1-carboxamide

pralnacasan

(1S,9S)-N-[(2R,3S)-2-éthoxy-5-oxotétrahydrofuran-3-yl]-9-[(isoquinoléin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-H-pyridazino[1,2-a]=[1,2]diazepine-1-carboxamide

pralnacasán

(1S,9S)-N-[(2R,3S)-2-etoxi-5-oxotetrahidrofuran-3-il]-9-[(isoquinolin-1-ilcarbonil)amino]-6,10-dioxooctahidro-6-H-piridazino[1,2-a][1,2]diazepina-1-carboxamida

 

C26H29N5O7

   
 

   

pratosartanum

 

pratosartan

2-propyl-3-[[2’-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-5,6,7,8-tetrahydrocycloheptaimidazol-4(3H)-one

pratosartan

2-propyl-3-[[2’-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-5,6,7,8-tétrahydrocycloheptaimidazol-4(3H)-one

pratosartán

2-propil-3-[[2’-(1H-tetrazol-5-il)bifenil-4-il]metil]-5,6,7,8-tetrahidrocicloheptaimidazol-4(3H)-ona

 

C25H26N6O

   
 

   

ragaglitazarum

 

ragaglitazar

(-)-(2S)-2-ethoxy-3-[4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl]propanoic acid

ragaglitazar

(-)-acide (2S)-2-éthoxy-3-[4-[2-(10H-phénoxazin-10-yl)éthoxy]phényl]=propanoïque

ragaglitazar

(-)-ácido (2S)-2-etoxi-3-[4-[2-(10H-fenoxazin-10-il)etoxi]fenil]propanoico

 

C25H25NO5

   
 

   

reslizumabum

 

reslizumab

immunoglobulin G4, anti-(human interleukin 5) (human-rat monoclonal SCH 55700 γ4-chain), disulfide with human-rat monoclonal SCH 55700 light chain, dimer

reslizumab

immunoglobuline G4, anti-(interleukine 5 humaine), (chaîne γ4 de l’anticorps monoclonal de rat humanisé SCH 55700), dimère du disulfure avec la chaîne légère de l’anticorps monoclonal de rat humanisé SCH 55700

reslizumab

immunoglobulina G4, anti-(interleukina 5 humana), (cadena γ4 del anticuerpo monoclonal humanizado de rata SCH 55700), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de rata SCH 55700

   

ruboxistaurinum

 

ruboxistaurin

(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,19H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-18,20-dione

ruboxistaurine

(9S)-9-[(diméthylamino)méthyl]-6,7,10,11-tétrahydro-9H,19H-5,21:12,17-diméthénodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadécène-18,20-dione

ruboxistaurina

(9S)-9-[(dimetilamino)metil]-6,7,10,11-tetrahidro-9H,19H-5,21:12,17-dimetenodibenzo[e,k]pirrolo[3,4-h][1,4,13]oxadiazaciclohexadeceno-18,20-diona

 

C28H28N4O3

   
 

   

semaxanibum

 

semaxanib

3-[(Z)-(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone

sémaxanib

(Z)-3-[(3,5-diméthyl-1H-pyrrol-2-yl)méthylène]-1,3-dihydro-2H-indol-2-one

semaxanib

3-[(Z)-(3,5-dimetilpirrol-2-il)metileno]-2-indolinona

 

C15H14N2O

   
 

   

senazodanum

 

senazodan

6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2H)-one

sénazodan

6-[4-(pyridin-4-ylamino)phényl]-4,5-dihydropyridazin-3(2H)-one

senazodán

6-[4-(piridin-4-ilamino)fenil]-4,5-dihidropiridazin-3(2H)-ona

 

C15H14N4O

   
 

   

silodosinum

 

silodosin

(-)-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]=ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide

silodosine

(-)-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroéthoxy)phénoxy]=éthyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide

silodosina

(-)-1-(3-hidroxipropil)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroetoxi)fenoxi]etil]=amino]propil]-2,3-dihidro-1H-indol-7-carboxamida

 

C25H32F3N3O4

   
 

   

solifenacinum

 

solifenacin

(3R)-1-azabicyclo[2.2.2]oct-3-yl(1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate

solifénacine

(1S)-1-phényl-3,4-dihydroisoquinoléine-2(1H)-carboxylate de (3R)-1-azabicyclo[2.2.2]oct-3-yle

solifenacina

(1S)-1-fenil-3,4-dihidroisoquinolina-2(1H)-carboxilato de (3R)-1-azabiciclo[2.2.2]oct-3-ilo

 

C23H26N2O2

   
 

   

tadalafilum

 

tadalafil

(6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1’,2’:1,6]pyrido[3,4-b]indole-1,4-dione

tadalafil

(6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1’,2’:1,6]pyrido[3,4-b]indole-1,4-dione

tadalafilo

(6R,12aR)-6-(1,3-benzodioxol-5-il)-2-metil-2,3,6,7,12,12a-hexahidropirazino[1’,2’:1,6]pirido[3,4-b]indol-1,4-diona

 

C22H19N3O4

   
 

   

tafluposidum

 

tafluposide

4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-ethylidene]-2,3-bisO-[(pentafluorophenoxy)acetyl]-β-D-glucopyranosyl]oxy]-6-oxo-5,5a,6,8,8a,9-hexahydrofuro[3’,4’:6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-2,6-dimethoxyphenyle dihydrogen phosphate

tafluposide

dihydrogénophosphate de 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-éthylidène]-2,3-bisO-[(pentafluorophénoxy)acétyl]-β-D-glucopyranosyl]oxy]-6-oxo-5,5a,6,8,8a,9-hexahydrofuro[3’,4’:6,7]naphto[2,3-d]-1,3-dioxol-5-yl]-2,6-diméthoxyphényle

taflupósido

dihidrógenofosfato de 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-etilideno]-2,3-bisO-[(pentafluorofenoxi)acetil]-β-D-glucopiranosil]oxi]-6-oxo-5,5a,6,8,8a,9-hexahidrofuro[3’,4’:6,7]nafto[2,3-d]-1,3-dioxol-5-il]-2,6-dimetoxifenilo

 

C45H35F10O20P

   
 

   

telberminum

 

telbermin

vascular endothelial growth factor (human), dimer

telbermine

facteur de croissance de l’endothélium vasculaire humain (dimère)

telbermina

factor de crecimiento del endotelio vascular (humano), dímero

 

C1612H2536N500O498S44

   
 

   

tenivastatinum

 

tenivastatin

(3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphtalen-1-yl]-3,5-dihydroxyheptanoic acid

ténivastatine

acide (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-diméthylbutanoyl)oxy]-2,6-diméthyl-1,2,6,7,8,8a-hexahydronaphtalén-1-yl]-3,5-dihydroxyheptanoïque

tenivastatina

ácido (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-dimetilbutanoil)oxi]-2,6-dimetil-1,2,6,7,8,8a-hexahidronaftalen-1-il]-3,5-dihidroxiheptanoico

 

C25H40O6

   
 

   

tesaglitazarum

 

tesaglitazar

(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]=propanoic acid

tésaglitazar

acide (2S)-2-éthoxy-3-[4-[2-[4-[(méthylsulfonyl)oxy]phényl]éthoxy]phényl]=propanoïque

tesaglitazar

ácido (2S)-2-etoxi-3-[4-[2-[4-[(metilsulfonil)oxi]fenil]etoxi]fenil]propanoico

 

C20H24O7S

   
 

   

tofimilastum

 

tofimilast

9-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine

tofimilast

9-cyclopentyl-7-éthyl-3-(thiophén-2-yl)-6,9-dihydro-5H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine

tofimilast

9-ciclopentil-7-etil-3-(tiofen-2-il)-6,9-dihidro-5H-pirazolo[3,4-c]-1,2,4-triazolo[4,3-a]piridina

 

C18H21N5S

   
 

   

xidecaflurum

 

xidecaflur

2,2-[(9Z)-9-octadecenylimino]diethanol hydrofluoride

xidécaflur

fluorhydrate de 2,2’-[(9Z)-octadec-9-énylimino]diéthanol

xidecaflur

hidrofluoruro de 2,2-[(9Z)-9-octadecenilimino]dietanol

 

C22H46FNO2

   
 

   

zanapezilum

 

zanapezil

3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propan-1-one

zanapézil

3-(1-benzylpipéridin-4-yl)-1-(2,3,4,5-tétrahydro-1H-benzazépin-8-yl)propan-1-one

zanapezilo

3-(1-bencilpiperidin-4-il)-1-(2,3,4,5-tetrahidro-1H-1-benzazepin-8-il)propan-1-ona

 

C25H32N2O

   
 

   

zonampanelum

 

zonampanel

[7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid

zonampanel

acide [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acétique

zonampanel

ácido [7-(1H-imidazol-1-il)-6-nitro-2,3-dioxo-3,4-dihidroquinoxalin-1(2H)-il]acético

 

C13H9N5O6

   
 

   

zoniporidum

 

zoniporide

N-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxamide

zoniporide

N-carbamimidoyl-5-cyclopropyl-1-(quinoléin-5-yl)-1H-pyrazole-4-carboxamide

zoniporida

N-carbamimidoil-5-ciclopropil-1-(quinolin-5-il)-1H-pyrazol-4-carboxamida

 

C17H16N6O

   
 

   

zoticasonum

 

zoticasone

S-[(3R)-2-oxotetrahydrofuran-3-yl] 6α,9-difluoro-12β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate

zoticasone

6α,9-difluoro-12β,17-dihydroxy-16α-méthyl-3-oxoandrosta-1,4-diène-17β-carbothioate de S-[(3R)-2-oxotétrahydrofuran-3-yle]

zoticasona

6α,9-difluoro-12β,17-dihidroxi-16α-metil-3-oxoandrosta-1,4-dieno-17β-carbotioato de S-[(3R)-2-oxotetrahidrofuran-3-ilo]

 

C25H30F2O6S

   
 

AMENDMENTS TO PREVIOUS LISTS/MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES/MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Nonproprietary Names (Prop. INN): List 59
Dénominations communes internationales proposées (DCI Prop.): Liste 59
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 59
(WHO Drug Information/Informations pharmaceutiques OMS/Informaciones farmacéuticas de la OMS, Vol. 2, No. 2, 1988)

     

p. 16

delete/supprimer/suprimase

insert/insérer/insértese

 

levoglutamidum

glutaminum

 

levoglutamide

glutamine

 

lévoglutamide

glutamine

 

levoglutamida

glutamina

     

Recommended International Nonproprietary Names (Rec. INN): List 42
Dénominations communes internationales recommandées (DCI Rec.): Liste 42
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 42
(WHO Drug Information, Vol. 13, No. 3, 1999)

     
 

suprimase

insértese

p. 184

carabersato

carabersat

p. 207

tonabersato

tonabersat

     

Recommended International Nonproprietary Names (Rec. INN): List 44
Dénominations communes internationales recommandées (DCI Rec.): Liste 44
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

     

p. 199

delete/supprimer/suprimase

insert/insérer/insértese

 

nebostinelum

neboglaminum

 

nebostinel

neboglamine

 

nébostinel

néboglamine

 

nebostinel

neboglamina

p. 199

onerceptum

 
 

onercept

replace the description by the following:
TNF-BP-(20-180)-peptide (part of extracellular domain of the glycosylated human Tumor Necrosis Factor Receptor 1)

 

onercept

sustitúyase la descripción por la siguiente:
péptido (20-180) TNF-BP (parte del dominio extracelular del receptor 1 humano del factor de necrosis tumoral glicosilado)

     

Recommended International Nonproprietary Names (Rec. INN): List 45
Dénominations communes internationales recommandées (DCI Rec.): Liste 45
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 45
(WHO Drug Information, Vol. 15, No. 1, 2001)

     

p. 55

evernimicinum

 
 

evernimicina

sustitúyase la descripción por la siguiente:
O-3-C-metil-4-O-metil-3-nitro-2,3,6-tridesoxi-α-L-arabino-hexopiranosil-(1→3)-O-4-O-(3,5-dicloro-4-hidroxi-2-metoxi-6-metilbenzoil)-2,6-didesoxi-β-D-arabino-hexopiranosil-(1→4)-O-(1R)-2,6-didesoxi-D-arabino-hexopiranosilideno-(1→3-4)-O-3-C-metil-6-desoxi-β-D-manopiranosil-(1→3)-O-4-O-metil-6-desoxi-β-D-galactopiranosil-(1→4)-2,6-di-O-metil-β-D-manopiranosido de O-(1R)-4-O-(2,4-dihidroxi-6-metilbenzoil)-2,3-O-metileno-D-xilopiranosilideno-(1→3-4)-α-L-lixopiranosilo

Procedure and Guiding Principles/Procédure et Directives/Procedimientos y principios generales

The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018